Pacific Biosciences of California Inc. (NASDAQ:PACB) is one of the 8 Best Life Sciences Penny Stocks to Buy.
On March 18, Pacific Biosciences of California Inc. (NASDAQ:PACB) revealed that Basecamp Research, a novel artificial intelligence research lab dedicated to the development of therapeutics, has chosen PacBio’s highly accurate (HiFi) sequencing on the company’s Revio platform. This will be utilized for the delivery of large-scale environmental and associated host metagenomic datasets to enable the Trillion Gene Atlas program. This is a pioneering scientific endeavor that seeks to generate and model biological data at the trillion-gene level.
Pressmaster/Shutterstock.com
This collaboration is expected to generate around 100,000 samples that will be extensively sequenced to produce the largest and most diverse metagenomics database compiled to date, covering more than 31 countries on five different continents. With advancements being made in AI modeling to facilitate biological designs, the performance of AI models largely depends on the nature of the datasets used in the training process.
On March 6, Barclays lowered its price target on Pacific Biosciences of California, Inc. (NASDAQ:PACB) from $2 to $1.5. The firm also downgraded the rating from Equal Weight to Underweight. This downward revision comes due to the expectations of a difficult market environment in the immediate future.
Amid the competitive launches across the sequencing space, the firm has anticipated a potential pause in the overall demand. Consequently, in the first half of 2026, the company might see a temporary drop in consumable sales, due to clients purposefully postponing their research projects in preparation for the launch of the SPRQ NX platform.
Pacific Biosciences of California Inc. (NASDAQ:PACB) is involved in designing and producing sequencing systems to solve genetically complex problems around the globe. It serves genome centers, public health labs, hospitals, and more by selling them technologies which include single-molecule real-time (SMRT) technology, SMRTbell and Revio, Vega, and Sequel instruments.
While we acknowledge the risk and potential of PACB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PACB and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.